Tumour size was reduced, and mouse survival improved in both gefitinib- and anti-PD-1 antibody-treated mice (Fig. 5f–j), with no significant changes in body weight (Supplementary Fig. 9a) and minimal cytotoxicity in the liver and kidney (Supplementary Fig. 9b). This evidence concerns the gene PDCD1 and neoplasm.